1. Home
  2. FNLC vs RLMD Comparison

FNLC vs RLMD Comparison

Compare FNLC & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp Inc  (ME)

FNLC

First Bancorp Inc (ME)

HOLD

Current Price

$36.64

Market Cap

387.9M

Sector

Finance

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$3.29

Market Cap

461.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNLC
RLMD
Founded
1864
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
387.9M
461.9M
IPO Year
1995
2012

Fundamental Metrics

Financial Performance
Metric
FNLC
RLMD
Price
$36.64
$3.29
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $10.75
AVG Volume (30 Days)
33.4K
★ 1.4M
Earning Date
10-21-2026
11-12-2026
Dividend Yield
★ 4.20%
N/A
EPS Growth
26.34
★ 45.28
EPS
★ 1.65
N/A
Revenue
N/A
★ $13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$21.84
★ N/A
Revenue Growth
N/A
★ 154.83
52 Week Low
$24.39
$2.15
52 Week High
$36.30
$8.00

Technical Indicators

Market Signals
Indicator
FNLC
RLMD
Relative Strength Index (RSI) 70.93 39.10
Support Level $34.28 $3.13
Resistance Level N/A $3.55
Average True Range (ATR) 0.94 0.21
MACD 0.35 0.03
Stochastic Oscillator 100.00 39.57

Price Performance

Historical Comparison
FNLC
RLMD

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services, including deposit accounts and consumer, commercial, and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: